ZA201104620B - Zaleplon gastroretentive drug delivery system - Google Patents

Zaleplon gastroretentive drug delivery system

Info

Publication number
ZA201104620B
ZA201104620B ZA2011/04620A ZA201104620A ZA201104620B ZA 201104620 B ZA201104620 B ZA 201104620B ZA 2011/04620 A ZA2011/04620 A ZA 2011/04620A ZA 201104620 A ZA201104620 A ZA 201104620A ZA 201104620 B ZA201104620 B ZA 201104620B
Authority
ZA
South Africa
Prior art keywords
delivery system
drug delivery
gastroretentive drug
zaleplon gastroretentive
zaleplon
Prior art date
Application number
ZA2011/04620A
Other languages
English (en)
Inventor
Suher Masri
David Kirmayer
Giora Carni
Eytan Moor
Elena Kluev
Nadav Navon
Original Assignee
Intec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intec Pharma Ltd filed Critical Intec Pharma Ltd
Publication of ZA201104620B publication Critical patent/ZA201104620B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/04620A 2008-12-04 2011-06-22 Zaleplon gastroretentive drug delivery system ZA201104620B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12005108P 2008-12-04 2008-12-04
PCT/IB2009/007731 WO2010064139A2 (en) 2008-12-04 2009-10-19 Zaleplon gastroretentive drug delivery system

Publications (1)

Publication Number Publication Date
ZA201104620B true ZA201104620B (en) 2012-03-28

Family

ID=42232930

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/04620A ZA201104620B (en) 2008-12-04 2011-06-22 Zaleplon gastroretentive drug delivery system

Country Status (11)

Country Link
US (2) US9693981B2 (OSRAM)
EP (1) EP2378883B1 (OSRAM)
JP (2) JP2012510987A (OSRAM)
KR (1) KR20110116004A (OSRAM)
CN (1) CN102300463B (OSRAM)
CA (1) CA2745741A1 (OSRAM)
ES (1) ES2562925T3 (OSRAM)
IL (1) IL213376A (OSRAM)
PL (1) PL2378883T3 (OSRAM)
WO (2) WO2010064139A2 (OSRAM)
ZA (1) ZA201104620B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101601649B1 (ko) 2008-04-18 2016-03-09 인텍 파마 리미티드 카르비도파／레보도파 위체류 약물 전달
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20130078290A1 (en) * 2010-06-01 2013-03-28 Rubicon Research Private Limited Gastroretentive Dosage Forms Of GABA Analogs
HUE038653T2 (hu) * 2011-03-01 2018-11-28 Pharnext Neurológiai rendellenességek baclofen és acamprosate alapú terápiája
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013180796A1 (en) 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Methods for treating insomnia
WO2014039951A1 (en) * 2012-09-10 2014-03-13 Novartis Ag Enteral pharmaceutical compositions
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2015038854A1 (en) 2013-09-13 2015-03-19 R.P. Scherer Technologies, Llc Encased-pellet tablets
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
FI3725357T3 (fi) 2014-06-11 2024-12-13 Massachusetts Inst Technology Pidättyviä rakenteita ja niihin liittyviä menetelmiä
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US10881619B2 (en) * 2014-12-29 2021-01-05 Boston Scientific Scimed, Inc. Compositions, devices and methods for multi-stage release of chemotherapeutics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
JP7189772B2 (ja) 2016-05-27 2022-12-14 リンドラ セラピューティクス， インコーポレイティド 胃内滞留システムのための材料構造物
US20190224118A1 (en) * 2016-07-11 2019-07-25 Intec Pharma Ltd. Oral gastroretentive formulations and uses thereof
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
EP3612196A4 (en) * 2017-04-18 2021-01-13 Actorius Innovations and Research Pvt. Ltd. Polymer based formulation for release of drugs and bioactives at specific git sites
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
CA3066658A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
US11980610B2 (en) * 2017-10-31 2024-05-14 Samyang Holdings Corporation Oral solid dosage form composition having improved disintegration and preparation method therefor
AU2020240108B2 (en) * 2019-03-20 2025-12-04 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
CN113840596A (zh) * 2019-03-20 2021-12-24 林德拉治疗公司 用于胃滞留剂型的衣层
US10792262B1 (en) * 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
US11491125B1 (en) 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations
WO2023141524A2 (en) * 2022-01-19 2023-07-27 Lyndra Therapeutics, Inc. Dosage forms for gastric retention

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH07179334A (ja) * 1993-12-22 1995-07-18 Sanei Touka Kk カプセル及びカプセル剤の製造方法
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10004790B4 (de) 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
MXPA03012041A (es) 2001-07-04 2004-03-26 Sun Pharmaceutical Ind Ltd Sistema de administracion controlada de farmacos de retencion gastrica.
US20080081834A1 (en) * 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
KR100553887B1 (ko) * 2003-06-24 2006-02-24 삼성전자주식회사 수직 및 수평으로 광시야각을 갖는 영상표시용 스크린 및이를 구비하는 프로젝션 텔레비전
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
EP1523981A1 (en) 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
JP2007510733A (ja) * 2003-11-05 2007-04-26 サンタラス インコーポレイティッド プロトンポンプ阻害剤および睡眠剤の併用
EP1535952B1 (en) * 2003-11-28 2013-01-16 Universite Louis Pasteur Method for preparing crosslinked polyelectrolyte multilayer films
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
JP4756835B2 (ja) * 2004-07-14 2011-08-24 キヤノン株式会社 生化学反応カートリッジ
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
JP5203965B2 (ja) * 2005-12-23 2013-06-05 クラフト・フーズ・グローバル・ブランズ・エルエルシー メントールと同様の感覚をもたらす組成物
US8298574B2 (en) * 2006-01-18 2012-10-30 Intec Pharma Ltd. Method and apparatus for forming delivery devices for oral intake of an agent
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
CA2674610C (en) * 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
EP1970056A1 (en) 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment

Also Published As

Publication number Publication date
US20110091542A1 (en) 2011-04-21
WO2010064139A3 (en) 2010-09-10
KR20110116004A (ko) 2011-10-24
WO2010064139A2 (en) 2010-06-10
IL213376A0 (en) 2011-07-31
JP2012510987A (ja) 2012-05-17
JP2015028094A (ja) 2015-02-12
EP2378883A2 (en) 2011-10-26
WO2010064100A1 (en) 2010-06-10
EP2378883A4 (en) 2014-03-05
CN102300463B (zh) 2015-03-25
US9693981B2 (en) 2017-07-04
CA2745741A1 (en) 2010-06-10
CN102300463A (zh) 2011-12-28
EP2378883B1 (en) 2015-12-23
ES2562925T3 (es) 2016-03-09
PL2378883T3 (pl) 2016-06-30
JP6104873B2 (ja) 2017-03-29
US20120021051A1 (en) 2012-01-26
IL213376A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
ZA201104620B (en) Zaleplon gastroretentive drug delivery system
IL210590A0 (en) Progestin-cotaining drug delivery system
ZA201002014B (en) Drug delivery system
EP2401012A4 (en) ACTIVE RELEASE SYSTEM
PT2398500T (pt) Sistema de entrega de medicamentos à base de glutationas
IL207366A0 (en) Drug delivery system with wireless nonitor
IL208708A0 (en) Carbidopa/lipodopa gastroretentive drug delivery
EP2178598A4 (en) IONTOPHORETIC DRUG DISTRIBUTION SYSTEM
SG175137A1 (en) Drug delivery composition
IL198911A0 (en) Drug delivery
IL213687A0 (en) Pharmaceutical dosages delivery system
IL215222A (en) A drug release device
IL212767A (en) Device for administering drugs
IL215219A0 (en) Drug delivery device
IL215220A0 (en) Drug delivery device
IL212357A0 (en) Sustained drug delivery system
IL212195A0 (en) Sustained release drug delivery system
EP2506909A4 (en) ACTIVE RELEASE DEVICE
PL2437736T3 (pl) Systemy dostarczania leków
IL213577A0 (en) Drug delivery device
EP2328511A4 (en) ACTIVE RELEASE IMPLANTS
GB201006818D0 (en) Drug delivery
IL212603A0 (en) Combined drug administration
ZA201006517B (en) Estradiol-containing drug delivery system
GB0817486D0 (en) Delivery system